Categories
Change Password!
Reset Password!
Elinzanetant markedly reduces the frequency and severity of menopausal vasomotor symptoms while improving sleep and quality of life.
In a study issued in “JAMA”, Elinzanetant (120 mg) proved to be an effective and well-tolerated non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) related to menopause. It also improved disturbed sleep patterns and menopause-linked quality of life, with an acceptable safety profile.
There is a critical demand for safe and effective nonhormonal therapies to address menopausal VMS. Hence, Elinzanetant (a selective neurokinin-1,3 receptor antagonist) was examined for its usefulness in postmenopausal subjects (aged 40 to 65) experiencing moderate-to-severe VMS. In two trials (OASIS 1 and OASIS 2), volunteers were assigned to receive either once-daily oral
Elinzanetant (OASIS 1: n = 199; OASIS 2: n = 200) or placebo (OASIS 1: n = 197; OASIS 2: n = 200).
In the trials, the enrolled subjects were given Elinzanetant (120 mg) for 26 weeks or a matching placebo for the first 12 weeks. This was followed by Elinzanetant (120 mg) for the next 14 weeks. A total of 309 (78.0%) subjects completed OASIS 1, and 324 (81.0%) completed OASIS 2. Baseline VMS frequency was 13.4 (Standard deviation [SD]: 6.6) for Elinzanetant and 14.3 (SD: 13.9) for placebo in OASIS 1; 14.7 (SD: 11.1) for Elinzanetant and 16.2 (SD: 11.2) for placebo in OASIS 2.
Elinzanetant markedly decreased VMS frequency in the 4th week (OASIS 1: −3.3; OASIS 2: −3.0) and in the 12th week (OASIS 1: −3.2; OASIS 2: −3.2). VMS severity improved at 4th week (OASIS 1: −0.3; OASIS 2: −0.2) and 12th week (OASIS 1: −0.4; OASIS 2: −0.3). Elinzanetant also ameliorated sleep irregularities and quality of life at 12th week, with a good safety profile. These findings highlight Elinzanetant’s potential for tackling menopausal symptoms.
JAMA Journal
Elinzanetant for the Treatment of Vasomotor Symptoms Associated with Menopause
Joann V. Pinkerton et al.
Comments (0)